Ensoma

The future of medicine lies within us.

[Ensoma @EnsomaBio]

Ensoma CEO Jim Burns joined leaders across biotech at #BIO2026 for conversations on the future of genetic medicine and therapeutic innovation.

It was an energizing week in San Diego, and we're proud to be part of a community advancing the possibilities of genetic medicine.

[Ensoma @EnsomaBio]

CEO Jim Burns will join leaders from @KitePharma, @FredHutch, @ChildrensPhila, and @RTWInstitute at #BIO2026 to discuss the future of in vivo HSC engineering and one-time genetic medicines. Learn more: https://t.co/FkYBIewyYA

[Ensoma @EnsomaBio]

The Ensoma team recently gathered at Flight Club Boston for a fun evening of connection, conversation, and friendly competition. We're grateful for opportunities to spend time together and strengthen the relationships that support our work every day.

[Ensoma @EnsomaBio]

It was an impactful week at #ASGCT2026 connecting with researchers, clinicians, advocates, and the gene and #celltherapy community. We’re grateful to be part of a community committed to advancing new therapies for patients and their loved ones.

[Ensoma @EnsomaBio]

Today, we announced the presentation of initial clinical data from the 1st participant dosed in our Phase 1/2 trial for X-CGD at #ASGCT2026. The data represent the first reported clinical experience with an in vivo hematopoietic stem cell-directed therapy. https://t.co/2F87ky405o

[Ensoma @EnsomaBio]

We're pleased to share that Professor Claire Booth and Dr. Morna Dorsey will present the following posters on our latest research in #CGD during the @ClinImmSoc Annual Meeting! Additional details about this year's meeting & poster viewing sessions here. https://t.co/sWUXSpDalN

[Ensoma @EnsomaBio]

This week, we visited the @AstraZeneca Hope Lodge in Boston, helping to prepare & serve a meal for patients & caregivers. The Lodge offers a supportive, home-like community during a deeply complex time. We were honored to spend time with and support such a resilient community.

[Ensoma @EnsomaBio]

Primary immunodeficiencies manifest in many ways & recurring infections are often dismissed, delaying diagnosis. During PI Month, we’re raising awareness of diseases like CGD & the need for new therapies. More on EN-374, an investigational therapy for CGD: https://t.co/CZO0sB3ROI

[Ensoma @EnsomaBio]

After a snowy delay, we joined our Seaport neighbors for a belated #SeaportForRare walk. We’re proud to stand alongside this community in support of the >300M patients and families affected by a rare disease. 🦓

[Ensoma @EnsomaBio]

Next week, Ensoma CEO Jim Burns will be part of @LifeSciEvents Drug Development & Delivery Day. Jim will join other industry leaders for the panel session “Advancing the Next Generation of Large Molecule Innovation." Register today! https://t.co/JGDblTgWDI

[Ensoma @EnsomaBio]

For #RareDiseaseDay this weekend, we gathered for a breakfast w/ @immunedeficienC Board Trustee Mark. Rare diseases affect 300M+ people worldwide. Behind every diagnosis is someone navigating uncertainty & hope. We’re proud to advance science for communities needing new options.

[Ensoma @EnsomaBio]

#WorldCancerDay reminds us that while meaningful progress has been made in cancer treatment, many are still waiting for new options. Our work is guided by our commitment to advancing #immunooncology for those who need it most. Our Director of Immuno-Oncology shares more below.

[Ensoma @EnsomaBio]

🎙️ Thanks to @ASGCTherapy for having CEO Jim Burns on the latest episode of The Issue! Listen in below as Jim & host Emily Walsh Martin discuss our platform's potential to greatly impact genetic disease & immune oncology, & what it could mean for patients. https://t.co/VbOUjrdSIv

[Ensoma @EnsomaBio]

We look forward to #JPM26 and connecting with members of the biotech community. Our team will be on site throughout the week & welcome opportunities to connect & share more about our work on the first-ever clinical-stage, in vivo HSC-directed gene insertion therapy. See you soon!

[Ensoma @EnsomaBio]

As 2025 comes to a close, we are especially grateful for the incredible contributions of team members throughout our journey, the support of our partners, patients & our community who helped shape Ensoma's growth into a clinical-stage company. Wishing you a joyful holiday season!

[Ensoma @EnsomaBio]

After announcing last week that the first patient in our multinational Phase 1/2 trial of EN-374 in #XCGD was successfully dosed, today, we’re pleased to share that the U.K. MHRA has cleared our CTA application for the program. Learn more: https://t.co/ZEkHmIe60w

[Ensoma @EnsomaBio]

Today, we're excited to announce the first patient has been dosed in the Phase 1/2 clinical trial of EN-374 for treatment of #XCGD, marking the first time an in vivo HSC-directed gene insertion therapy has been evaluated in a patient. Hear more below. https://t.co/jTlVEBXl5c

[Ensoma @EnsomaBio]

It's been a great week at #SITC25. Scientists Alvin P. & Yiwen Z. will present posters on our in vivo, HSC-derived CAR-M, NK & T platform's anti-tumor activity & its potential to generate lineage-restricted CAR cells in #solidtumors this evening, 11/7 & tomorrow, 11/8. Join us!

[Ensoma @EnsomaBio]

We're pioneering one-time, off-the-shelf therapies that reprogram HSCs to treat disease with unprecedented versatility. We're honored to receive the @Biotech_Awards for #GeneEditing Platform of the Year! We remain driven to improve the patient experience for genomic medicine.

[Ensoma @EnsomaBio]

This week at #SITC25, we're pleased to announce preclinical data demonstrating proof-of-concept for our in vivo, HSC-derived CAR-M, NK, & T platform, including its anti-tumor activity & potential to generate lineage-restricted CAR cells in #solidtumors. https://t.co/97biaZ3Hx8